Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | TP53 wild-type |
| Therapy | Ad.p53-DC vaccine |
| Indication/Tumor Type | ovarian cancer |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| TP53 wild-type | ovarian cancer | predicted - sensitive | Ad.p53-DC vaccine | Phase I | Actionable | In Phase I and Phase II clinical trials, various forms of p53 gene therapy (such as adenoviral-p53) have been shown to be generally safe and have demonstrated clinical efficacy in patients with ovarian cancer (PMID: 12082455; PMID: 19621448; PMID: 21927947; PMID: 15297186; PMID: 12082456). | 15297186 21927947 19621448 12082455 12082456 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (12082455) | A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. | Full reference... |
| (12082456) | Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500. | Full reference... |
| (15297186) | A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer. | Full reference... |
| (19621448) | Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. | Full reference... |
| (21927947) | A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. | Full reference... |